Piper Sandler on Design Therapeutics Inc (DSGN): 'Execution Is Full Gear Mode With a Catalyst Rich 2H26'
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $12.00 price target on Design Therapeutics Inc (NASDAQ: DSGN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
